z-logo
Premium
X‐waiver battle over buprenorphine heats up
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30558
Subject(s) - waiver , buprenorphine , (+) naloxone , medicine , food and drug administration , license , opioid use disorder , schedule , opioid , pharmacology , law , computer science , political science , receptor , operating system
As buprenorphine — a schedule III medication approved for the treatment of opioid use disorder when provided in a combination product (that includes naloxone), such as Suboxone — has special prescribing requirements. No matter how thorough your training as a clinician, you have to receive an X‐waiver from the Drug Enforcement Administration (DEA), in addition to your DEA license, in order to be able to prescribe it.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here